Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection

{ 'indexed': {'date-parts': [[2024, 3, 29]], 'date-time': '2024-03-29T08:20:41Z', 'timestamp': 1711700441759}, 'reference-count': 56, 'publisher': 'Springer Science and Business Media LLC', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2021, 5, 27]], 'date-time': '2021-05-27T00:00:00Z', 'timestamp': 1622073600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}, { 'start': { 'date-parts': [[2021, 5, 27]], 'date-time': '2021-05-27T00:00:00Z', 'timestamp': 1622073600000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'abstract': '<jats:title>Abstract</jats:title><jats:p>In a randomized clinical trial of 86 hospitalized ' 'COVID-19 patients comparing standard care to treatment with\xa0300mL convalescent plasma ' 'containing high titers of neutralizing SARS-CoV-2 antibodies, no overall clinical benefit was ' 'observed. Using a comprehensive translational approach, we unravel the virological and ' 'immunological responses following treatment to disentangle which COVID-19 patients may ' 'benefit and should be the focus of future studies. Convalescent plasma is safe, does not ' 'improve survival, has no effect on the disease course, nor does plasma enhance viral ' 'clearance in the respiratory tract, influence SARS-CoV-2 antibody development or serum ' 'proinflammatory cytokines levels. Here, we show that the vast majority of patients already ' 'had potent neutralizing SARS-CoV-2 antibodies at hospital admission and with comparable ' 'titers to carefully selected plasma donors. This resulted in the decision to terminate the ' 'trial prematurely. Treatment with convalescent plasma should be studied early in the disease ' 'course or at least preceding autologous humoral response development.</jats:p>', 'DOI': '10.1038/s41467-021-23469-2', 'type': 'journal-article', 'created': {'date-parts': [[2021, 5, 27]], 'date-time': '2021-05-27T10:12:23Z', 'timestamp': 1622110343000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 124, 'title': 'Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for ' 'severe SARS-CoV-2 infection', 'prefix': '10.1038', 'volume': '12', 'author': [ {'given': 'Arvind', 'family': 'Gharbharan', 'sequence': 'first', 'affiliation': []}, {'given': 'Carlijn C. E.', 'family': 'Jordans', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-7678-314X', 'authenticated-orcid': False, 'given': 'Corine', 'family': 'GeurtsvanKessel', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jan G.', 'family': 'den Hollander', 'sequence': 'additional', 'affiliation': []}, {'given': 'Faiz', 'family': 'Karim', 'sequence': 'additional', 'affiliation': []}, {'given': 'Femke P. N.', 'family': 'Mollema', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-1486-3045', 'authenticated-orcid': False, 'given': 'Janneke E.', 'family': 'Stalenhoef – Schukken', 'sequence': 'additional', 'affiliation': []}, {'given': 'Anthonius', 'family': 'Dofferhoff', 'sequence': 'additional', 'affiliation': []}, {'given': 'Inge', 'family': 'Ludwig', 'sequence': 'additional', 'affiliation': []}, {'given': 'Adrianus', 'family': 'Koster', 'sequence': 'additional', 'affiliation': []}, {'given': 'Robert-Jan', 'family': 'Hassing', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jeannet C.', 'family': 'Bos', 'sequence': 'additional', 'affiliation': []}, {'given': 'Geert R.', 'family': 'van Pottelberge', 'sequence': 'additional', 'affiliation': []}, {'given': 'Imro N.', 'family': 'Vlasveld', 'sequence': 'additional', 'affiliation': []}, {'given': 'Heidi S. M.', 'family': 'Ammerlaan', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Elena M.', 'family': 'van Leeuwen – Segarceanu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jelle', 'family': 'Miedema', 'sequence': 'additional', 'affiliation': []}, {'given': 'Menno', 'family': 'van der Eerden', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-6693-4725', 'authenticated-orcid': False, 'given': 'Thijs J.', 'family': 'Schrama', 'sequence': 'additional', 'affiliation': []}, {'given': 'Grigorios', 'family': 'Papageorgiou', 'sequence': 'additional', 'affiliation': []}, {'given': 'Peter', 'family': 'te Boekhorst', 'sequence': 'additional', 'affiliation': []}, {'given': 'Francis H.', 'family': 'Swaneveld', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-4654-7509', 'authenticated-orcid': False, 'given': 'Yvonne M.', 'family': 'Mueller', 'sequence': 'additional', 'affiliation': []}, {'given': 'Marco W. J.', 'family': 'Schreurs', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jeroen J. A.', 'family': 'van Kampen', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-2463-027X', 'authenticated-orcid': False, 'given': 'Barry', 'family': 'Rockx', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-2394-1079', 'authenticated-orcid': False, 'given': 'Nisreen M. A.', 'family': 'Okba', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-7690-5218', 'authenticated-orcid': False, 'given': 'Peter D.', 'family': 'Katsikis', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-5204-2312', 'authenticated-orcid': False, 'given': 'Marion P. G.', 'family': 'Koopmans', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-6221-2015', 'authenticated-orcid': False, 'given': 'Bart L.', 'family': 'Haagmans', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-1904-6450', 'authenticated-orcid': False, 'given': 'Casper', 'family': 'Rokx', 'sequence': 'additional', 'affiliation': []}, {'given': 'Bart J. A.', 'family': 'Rijnders', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2021, 5, 27]]}, 'reference': [ { 'key': '23469_CR1', 'doi-asserted-by': 'publisher', 'first-page': '693', 'DOI': '10.1056/NEJMoa2021436', 'volume': '384', 'author': 'RECOVERY Collaborative Group', 'year': '2021', 'unstructured': 'RECOVERY Collaborative Group. Dexamethasone in hospitalized patients ' 'with Covid-19. N Engl J Med.\xa0384, 693–704 (2021).', 'journal-title': 'N Engl J Med.'}, { 'key': '23469_CR2', 'doi-asserted-by': 'publisher', 'unstructured': 'Beigel, J. H. et al. Remdesivir for the treatment of Covid-19 — final ' 'report. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2007764 (2020).', 'DOI': '10.1056/NEJMoa2007764'}, { 'key': '23469_CR3', 'doi-asserted-by': 'publisher', 'first-page': '497', 'DOI': '10.1056/NEJMoa2023184', 'volume': '384', 'author': 'H Pan', 'year': '2021', 'unstructured': 'Pan, H. et al. Repurposed antiviral drugs for COVID-19 —\xa0interim WHO ' 'SOLIDARITY trial results. WHO Solidarity Trial Consortium.\xa0N Engl J ' 'Med.\xa0384, 497–511\xa0(2021).', 'journal-title': 'N Engl J Med.'}, { 'key': '23469_CR4', 'unstructured': 'Study assessing the safety, tolerability, pharmacokinetics, and ' 'immunogenicity of repeated subcutaneous doses of anti-spike (S) ' 'SARS-CoV-2 monoclonal antibodies (REGN10933+REGN10987) in adult ' 'volunteers as related to COVID-19, ' 'https://clinicaltrials.gov/ct2/show/study/NCT04519437?term=Regeneron+Pharmaceuticals&cond=%22Coronavirus+Infections%22&draw=2&rank=2#wrapper ' '(accessed 20 October 2020).'}, { 'key': '23469_CR5', 'unstructured': 'Safety, tolerability, and efficacy of anti-spike (S) SARS-CoV-2 ' 'monoclonal antibodies for the treatment of ambulatory adult patients ' 'with COVID-19, ' 'https://clinicaltrials.gov/ct2/show/NCT04425629?term=Regeneron+Pharmaceuticals&cond=%22Coronavirus+Infections%22&draw=2&rank=3 ' '(accessed 20 October 2020).'}, { 'key': '23469_CR6', 'unstructured': 'Safety, tolerability, and efficacy of anti-spike (S) SARS-CoV-2 ' 'monoclonal antibodies for hospitalized adult patients with COVID-19, ' 'https://clinicaltrials.gov/ct2/show/NCT04426695?term=Regeneron+Pharmaceuticals&cond=%22Coronavirus+Infections%22&draw=2&rank=4 ' '(accessed 20 October 2020).'}, { 'key': '23469_CR7', 'doi-asserted-by': 'publisher', 'first-page': '157895', 'DOI': '10.1155/2014/157895', 'volume': '2014', 'author': 'PJ Klasse', 'year': '2014', 'unstructured': 'Klasse, P. J. Neutralization of virus infectivity by antibodies: old ' 'problems in new perspectives. Adv. Biol. 2014, 157895 (2014).', 'journal-title': 'Adv. Biol.'}, { 'key': '23469_CR8', 'doi-asserted-by': 'publisher', 'first-page': '1134', 'DOI': '10.1038/s41551-020-00660-2', 'volume': '4', 'author': 'S Jiang', 'year': '2020', 'unstructured': 'Jiang, S., Zhang, X., Yang, Y., Hotez, P. J. & Du, L. Neutralizing ' 'antibodies for the treatment of COVID-19. Nat. Biomed. Eng. 4, 1134–1139 ' '(2020).', 'journal-title': 'Nat. Biomed. Eng.'}, { 'key': '23469_CR9', 'doi-asserted-by': 'publisher', 'unstructured': 'Carrillo, J. et al. Humoral immune responses and neutralizing antibodies ' 'against SARS-CoV-2; implications in pathogenesis and protective ' 'immunity. Biochem. Biophys. Res. Commun. ' 'https://doi.org/10.1016/j.bbrc.2020.10.108 (2020).', 'DOI': '10.1016/j.bbrc.2020.10.108'}, { 'key': '23469_CR10', 'doi-asserted-by': 'publisher', 'first-page': '1554', 'DOI': '10.3201/eid2209.151164', 'volume': '22', 'author': 'YM Arabi', 'year': '2016', 'unstructured': 'Arabi, Y. M. et al. Feasibility of using convalescent plasma ' 'immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg. Infect. Dis. ' '22, 1554–1561 (2016).', 'journal-title': 'Emerg. Infect. Dis.'}, { 'key': '23469_CR11', 'doi-asserted-by': 'publisher', 'first-page': '44', 'DOI': '10.1007/s10096-004-1271-9', 'volume': '24', 'author': 'Y Cheng', 'year': '2005', 'unstructured': 'Cheng, Y. et al. Use of convalescent plasma therapy in SARS patients in ' 'Hong Kong. Eur. J. Clin. Microbiol. Infect. Dis. 24, 44–46 (2005).', 'journal-title': 'Eur. J. Clin. Microbiol. Infect. Dis.'}, { 'key': '23469_CR12', 'doi-asserted-by': 'publisher', 'first-page': '464', 'DOI': '10.1378/chest.12-2907', 'volume': '144', 'author': 'IFN Hung', 'year': '2013', 'unstructured': 'Hung, I. F. N. et al. Hyperimmune IV immunoglobulin treatment: a ' 'multicenter double-blind randomized controlled trial for patients with ' 'severe 2009 influenza A(H1N1) infection. Chest 144, 464–473 (2013).', 'journal-title': 'Chest'}, { 'key': '23469_CR13', 'doi-asserted-by': 'publisher', 'first-page': '80', 'DOI': '10.1093/infdis/jiu396', 'volume': '211', 'author': 'J Mair-Jenkins', 'year': '2015', 'unstructured': 'Mair-Jenkins, J. et al. The effectiveness of convalescent plasma and ' 'hyperimmune immunoglobulin for the treatment of severe acute respiratory ' 'infections of viral etiology: a systematic review and exploratory ' 'meta-analysis. J. Infect. Dis. 211, 80–90 (2015).', 'journal-title': 'J. Infect. Dis.'}, { 'key': '23469_CR14', 'doi-asserted-by': 'publisher', 'unstructured': 'Haagmans, B. L. et al. SARS-CoV-2 neutralizing human antibodies protect ' 'against lower respiratory tract disease in a hamster model. Preprint at ' 'bioRxiv https://doi.org/10.1101/2020.08.24.264630 (2020).', 'DOI': '10.1101/2020.08.24.264630'}, { 'key': '23469_CR15', 'doi-asserted-by': 'publisher', 'first-page': 'E745', 'DOI': '10.1503/cmaj.200642', 'volume': '192', 'author': 'N Devasenapathy', 'year': '2020', 'unstructured': 'Devasenapathy, N. et al. Efficacy and safety of convalescent plasma for ' 'severe COVID-19 based on evidence in other severe respiratory viral ' 'infections: a systematic review and meta-analysis. Cmaj 192, E745–E755 ' '(2020).', 'journal-title': 'Cmaj'}, { 'key': '23469_CR16', 'first-page': 'CD013600', 'volume': '7', 'author': 'V Piechotta', 'year': '2020', 'unstructured': 'Piechotta, V. et al. Convalescent plasma or hyperimmune immunoglobulin ' 'for people with COVID-19: a living systematic review. Cochrane Database ' 'Syst. Rev. 7, CD013600 (2020).', 'journal-title': 'Cochrane Database Syst. Rev.'}, { 'key': '23469_CR17', 'doi-asserted-by': 'crossref', 'unstructured': 'Joyner, M. J. et al. Effect of Convalescent Plasma on Mortality among ' 'Hospitalized Patients with COVID-19: Initial Three-Month Experience. ' 'Preprint at medRxiv ' 'https://www.medrxiv.org/content/10.1101/2020.08.12.20169359v1\xa0(2020).', 'DOI': '10.1101/2020.08.12.20169359'}, { 'key': '23469_CR18', 'doi-asserted-by': 'crossref', 'unstructured': 'Li, L. et al. Effect of convalescent plasma therapy on time to clinical ' 'improvement in patients with severe and life-threatening COVID-19: a ' 'randomized clinical trial. JAMA 324, 1–11 (2020).', 'DOI': '10.1001/jama.2020.12607'}, { 'key': '23469_CR19', 'doi-asserted-by': 'publisher', 'first-page': '1582', 'DOI': '10.1001/jama.2020.4783', 'volume': '323', 'author': 'C Shen', 'year': '2020', 'unstructured': 'Shen, C. et al. Treatment of 5 critically ill patients with COVID-19 ' 'with convalescent plasma. JAMA 323, 1582–1589 (2020).', 'journal-title': 'JAMA'}, { 'key': '23469_CR20', 'doi-asserted-by': 'publisher', 'first-page': 'e9', 'DOI': '10.1016/j.chest.2020.03.039', 'volume': '158', 'author': 'B Zhang', 'year': '2020', 'unstructured': 'Zhang, B. et al. Treatment with convalescent plasma for critically ill ' 'patients with severe acute respiratory syndrome coronavirus 2 infection. ' 'Chest 158, e9–e13 (2020).', 'journal-title': 'Chest'}, { 'key': '23469_CR21', 'unstructured': 'COVID-19 expanded access program, https://www.uscovidplasma.org/ ' '(accessed 29 July 2020).'}, { 'key': '23469_CR22', 'doi-asserted-by': 'publisher', 'first-page': '9490', 'DOI': '10.1073/pnas.2004168117', 'volume': '117', 'author': 'K Duan', 'year': '2020', 'unstructured': 'Duan, K. et al. Effectiveness of convalescent plasma therapy in severe ' 'COVID-19 patients. Proc. Natl Acad. Sci. USA 117, 9490–9496 (2020).', 'journal-title': 'Proc. Natl Acad. Sci. USA'}, { 'key': '23469_CR23', 'unstructured': 'Joyner, M. J. et al. Early safety indicators of COVID-19 convalescent ' 'plasma in 5,000 patients. J. Clin. Invest. 130, 4791–4797 (2020).'}, { 'key': '23469_CR24', 'doi-asserted-by': 'publisher', 'first-page': '1708', 'DOI': '10.1038/s41591-020-1088-9', 'volume': '26', 'author': 'STH Liu', 'year': '2020', 'unstructured': 'Liu, S. T. H. et al. Convalescent plasma treatment of severe COVID-19: a ' 'matched control study. Nat Med 26, 1708–1713 (2020).', 'journal-title': 'Nat Med'}, { 'key': '23469_CR25', 'doi-asserted-by': 'publisher', 'first-page': '12', 'DOI': '10.3324/haematol.2019.244350', 'volume': '105', 'author': 'C Perotti', 'year': '2020', 'unstructured': 'Perotti, C. et al. Mortality reduction in 46 severe Covid-19 patients ' 'treated with hyperimmune plasma. A proof of concept single arm ' 'multicenter interventional trial.\xa0Haematologica. 105, 12\xa0(2020).', 'journal-title': 'Haematologica'}, { 'key': '23469_CR26', 'doi-asserted-by': 'crossref', 'unstructured': 'Pau, A. K. et al. Convalescent plasma for the treatment of COVID-19: ' 'perspectives of the National Institutes of Health COVID-19 treatment ' 'guidelines panel. Ann. Intern. Med. 174, 93–95 (2020).', 'DOI': '10.7326/M20-6448'}, { 'key': '23469_CR27', 'unstructured': 'U.S. Food and Drug Administration. Convalescent Plasma Letter of ' 'Authorization, August 2020, https://www.fda.gov/media/141477/download ' '(accessed 6 September 2020).'}, { 'key': '23469_CR28', 'unstructured': 'The Dutch National Institute for Public Health and Environment. COVID-19 ' 'Guideline (only available in Dutch), ' 'https://lci.rivm.nl/richtlijnen/covid-19 (accessed 5 October 2020, last ' 'updated 5 October 2020).'}, { 'key': '23469_CR29', 'unstructured': 'International Severe Acute Respiratory and Emerging Infections ' 'Consortium (ISARIC). COVID-19 Report 19 May 2020, ' 'https://media.tghn.org/medialibrary/2020/05/ISARIC_Data_Platform_COVID-19_Report_19MAY20.pdf ' '(accessed 27 May 2020).'}, { 'key': '23469_CR30', 'doi-asserted-by': 'publisher', 'first-page': '1054', 'DOI': '10.1016/S0140-6736(20)30566-3', 'volume': '395', 'author': 'F Zhou', 'year': '2020', 'unstructured': 'Zhou, F. et al. Clinical course and risk factors for mortality of adult ' 'inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. ' 'Lancet 395, 1054–1062 (2020).', 'journal-title': 'Lancet'}, { 'key': '23469_CR31', 'doi-asserted-by': 'publisher', 'first-page': '915', 'DOI': '10.1016/j.jamda.2020.05.045', 'volume': '21', 'author': 'C Bonanad', 'year': '2020', 'unstructured': 'Bonanad, C. et al. The effect of age on mortality in patients with ' 'COVID-19: a meta-analysis with 611,583 subjects. J. Am. Med. Dir. Assoc. ' '21, 915–918 (2020).', 'journal-title': 'J. Am. Med. Dir. Assoc.'}, { 'key': '23469_CR32', 'doi-asserted-by': 'publisher', 'first-page': '152', 'DOI': '10.3389/fpubh.2020.00152', 'volume': '8', 'author': 'J-M Jin', 'year': '2020', 'unstructured': 'Jin, J.-M. et al. Gender differences in patients with COVID-19: focus on ' 'severity and mortality. Front. Public Health 8, 152–152 (2020).', 'journal-title': 'Front. Public Health'}, { 'key': '23469_CR33', 'doi-asserted-by': 'publisher', 'first-page': 'ofaa153', 'DOI': '10.1093/ofid/ofaa153', 'volume': '7', 'author': 'G Wang', 'year': '2020', 'unstructured': 'Wang, G. et al. C-reactive protein level may predict the risk of ' 'COVID-19 aggravation. Open Forum Infect. Dis. 7, ofaa153–ofaa153 (2020).', 'journal-title': 'Open Forum Infect. Dis.'}, { 'key': '23469_CR34', 'doi-asserted-by': 'publisher', 'first-page': '12410', 'DOI': '10.18632/aging.103383', 'volume': '12', 'author': 'L Xu', 'year': '2020', 'unstructured': 'Xu, L., Mao, Y. & Chen, G. Risk factors for 2019 novel coronavirus ' 'disease (COVID-19) patients progressing to critical illness: a ' 'systematic review and meta-analysis. Aging (Albany NY) 12, 12410–12421 ' '(2020).', 'journal-title': 'Aging (Albany NY)'}, { 'key': '23469_CR35', 'doi-asserted-by': 'publisher', 'first-page': '131', 'DOI': '10.1016/j.ijid.2020.04.086', 'volume': '96', 'author': 'Q Zhao', 'year': '2020', 'unstructured': 'Zhao, Q. et al. Lymphopenia is associated with severe coronavirus ' 'disease 2019 (COVID-19) infections: a systemic review and meta-analysis. ' 'Int. J. Infect. Dis. 96, 131–135 (2020).', 'journal-title': 'Int. J. Infect. Dis.'}, { 'key': '23469_CR36', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41467-020-17317-y', 'volume': '11', 'author': 'CH GeurtsvanKessel', 'year': '2020', 'unstructured': 'GeurtsvanKessel, C. H. et al. An evaluation of COVID-19 serological ' 'assays informs future diagnostics and exposure assessment. Nat. Commun. ' '11, 3436 (2020).', 'journal-title': 'Nat. Commun.'}, { 'key': '23469_CR37', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41467-020-20568-4', 'volume': '12', 'author': 'JJA van Kampen', 'year': '2021', 'unstructured': 'van Kampen, J. J. A. et al. Shedding of infectious virus in hospitalized ' 'patients with coronavirus disease-2019 (COVID-19): duration and key ' 'determinants.\xa0Nat Comms. 12, 267 (2021).', 'journal-title': 'Nat Comms.'}, { 'key': '23469_CR38', 'doi-asserted-by': 'publisher', 'first-page': '465', 'DOI': '10.1038/s41586-020-2196-x', 'volume': '581', 'author': 'R Wölfel', 'year': '2020', 'unstructured': 'Wölfel, R. et al. Virological assessment of hospitalized patients with ' 'COVID-2019. Nature 581, 465–469 (2020).', 'journal-title': 'Nature'}, { 'key': '23469_CR39', 'doi-asserted-by': 'publisher', 'first-page': 'm3939', 'DOI': '10.1136/bmj.m3939', 'volume': '371', 'author': 'A Agarwal', 'year': '2020', 'unstructured': 'Agarwal, A. et al. Convalescent plasma in the management of moderate ' 'covid-19 in adults in India: open label phase II multicentre randomised ' 'controlled trial (PLACID Trial). BMJ 371, m3939 (2020).', 'journal-title': 'BMJ'}, { 'key': '23469_CR40', 'doi-asserted-by': 'publisher', 'first-page': '397', 'DOI': '10.1016/S1473-3099(11)70340-1', 'volume': '12', 'author': 'L Both', 'year': '2012', 'unstructured': 'Both, L. et al. Passive immunity in the prevention of rabies. Lancet ' 'Infect. Dis. 12, 397–407 (2012).', 'journal-title': 'Lancet Infect. Dis.'}, { 'key': '23469_CR41', 'doi-asserted-by': 'publisher', 'first-page': '1059', 'DOI': '10.1007/s10096-015-2341-x', 'volume': '34', 'author': 'R Orlando', 'year': '2015', 'unstructured': 'Orlando, R. et al. Prevention of hepatitis B virus infection: from the ' 'past to the future. Eur. J. Clin. Microbiol. Infect. Dis. 34, 1059–1070 ' '(2015).', 'journal-title': 'Eur. J. Clin. Microbiol. Infect. Dis.'}, { 'key': '23469_CR42', 'doi-asserted-by': 'crossref', 'unstructured': 'Okba, N. M. A. et al. Severe acute respiratory syndrome coronavirus ' '2-specific antibody responses in coronavirus disease 2019 patients. ' 'Emerg. Infect. Dis. 26, 1478–1488 (2020).', 'DOI': '10.3201/eid2607.200841'}, { 'key': '23469_CR43', 'doi-asserted-by': 'crossref', 'unstructured': 'Wang, X. et al. Neutralizing antibodies responses to SARS-CoV-2 in ' 'COVID-19 inpatients and convalescent patients. Clin. Infect. Dis. ' 'ciaa721 (2020).', 'DOI': '10.1101/2020.04.15.20065623'}, { 'key': '23469_CR44', 'doi-asserted-by': 'crossref', 'unstructured': 'Horby, P. et al. Dexamethasone in hospitalized patients with Covid-19 — ' 'preliminary report. N. Engl. J. Med. 384, 693–704 (2020).', 'DOI': '10.1056/NEJMoa2021436'}, { 'key': '23469_CR45', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41467-020-17317-y', 'volume': '11', 'author': 'CH GeurtsvanKessel', 'year': '2020', 'unstructured': 'GeurtsvanKessel, C. H. et al. An evaluation of COVID-19 serological ' 'assays informs future diagnostics and exposure assessment. Nat Comms. ' '11, 3346\xa0(2020).', 'journal-title': 'Nat Comms'}, { 'key': '23469_CR46', 'doi-asserted-by': 'publisher', 'unstructured': 'Long, Q.-X. et al. Clinical and immunological assessment of asymptomatic ' 'SARS-CoV-2 infections. Nat. Med. ' 'https://doi.org/10.1038/s41591-020-0965-6 (2020).', 'DOI': '10.1038/s41591-020-0965-6'}, { 'key': '23469_CR47', 'doi-asserted-by': 'publisher', 'unstructured': 'Petkova, E., Antman, E. M. & Troxel, A. B. Pooling data from individual ' 'clinical trials in the COVID-19 era. JAMA, ' 'https://doi.org/10.1001/jama.2020.13042 (2020).', 'DOI': '10.1001/jama.2020.13042'}, { 'key': '23469_CR48', 'doi-asserted-by': 'crossref', 'unstructured': 'Brouwer, P. J. M. et al. Potent neutralizing antibodies from COVID-19 ' 'patients define multiple targets of vulnerability. Science 369, 643–650 ' '(2020).', 'DOI': '10.1126/science.abc5902'}, { 'key': '23469_CR49', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41467-020-16256-y', 'volume': '11', 'author': 'C Wang', 'year': '2020', 'unstructured': 'Wang, C. et al. A human monoclonal antibody blocking SARS-CoV-2 ' 'infection. Nat. Commun. 11, 2251 (2020).', 'journal-title': 'Nat. Commun.'}, { 'key': '23469_CR50', 'unstructured': 'University of Oxford. RECOVERY Trial, https://www.recoverytrial.net/ ' '(accessed 31 July 2020).'}, { 'key': '23469_CR51', 'unstructured': 'REMAP-CAP, https://www.remapcap.org/ (accessed 31 July 2020).'}, { 'key': '23469_CR52', 'doi-asserted-by': 'publisher', 'first-page': '1015', 'DOI': '10.1056/NEJMoa2031893', 'volume': '384', 'author': 'MJ Joyner', 'year': '2021', 'unstructured': 'Joyner, M. J. et al. Convalescent plasma antibody levels and the risk of ' 'death from Covid-19. N Engl J Med. 384, 1015–1027 (2021).', 'journal-title': 'N Engl J Med.'}, { 'key': '23469_CR53', 'unstructured': 'Convalescent plasma to limit SARS-CoV-2 associated complications, ' 'https://clinicaltrials.gov/ct2/show/NCT04373460?term=sullivan&cond=covid&draw=2&rank=1 ' '(accessed 31 July 2020).'}, { 'key': '23469_CR54', 'unstructured': 'World Health Organizatin. Blueprint Novel Coronavirus COVID-19 ' 'Therapeutic Trial Synopsis, ' 'https://www.who.int/publications/i/item/covid-19-therapeutic-trial-synopsis ' '(2020).'}, { 'key': '23469_CR55', 'unstructured': 'The Dutch General Practicioner Association. Flu Vaccination: General ' 'Practicioner Guideline (only available in Dutch), ' 'https://www.nhg.org/sites/default/files/content/nhg_org/uploads/final_griep_sep_2020.pdf ' '(accessed 19 October 2020).'}, { 'key': '23469_CR56', 'doi-asserted-by': 'publisher', 'first-page': '496', 'DOI': '10.1080/01621459.1999.10474144', 'volume': '94', 'author': 'JP Fine', 'year': '1999', 'unstructured': 'Fine, J. P. & Gray, R. J. A proportional hazards model for the ' 'subdistribution of a competing risk. JASA. 94, 496–509 (1999).', 'journal-title': 'JASA.'}], 'container-title': 'Nature Communications', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.nature.com/articles/s41467-021-23469-2.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.nature.com/articles/s41467-021-23469-2', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.nature.com/articles/s41467-021-23469-2.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 12, 2]], 'date-time': '2022-12-02T12:46:29Z', 'timestamp': 1669985189000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.nature.com/articles/s41467-021-23469-2'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 5, 27]]}, 'references-count': 56, 'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2021, 12]]}}, 'alternative-id': ['23469'], 'URL': 'http://dx.doi.org/10.1038/s41467-021-23469-2', 'relation': { 'has-preprint': [ { 'id-type': 'doi', 'id': '10.1101/2020.07.01.20139857', 'asserted-by': 'object'}, { 'id-type': 'doi', 'id': '10.21203/rs.3.rs-105265/v1', 'asserted-by': 'object'}]}, 'ISSN': ['2041-1723'], 'subject': [ 'General Physics and Astronomy', 'General Biochemistry, Genetics and Molecular Biology', 'General Chemistry', 'Multidisciplinary'], 'container-title-short': 'Nat Commun', 'published': {'date-parts': [[2021, 5, 27]]}, 'assertion': [ { 'value': '9 November 2020', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '31 March 2021', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '27 May 2021', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': 'The Netherlands Organisation for Health Research and Development (ZonMW, grant ' 'agreement 10150062010008, B.L.H.), the Erasmus foundation grant (B.J.A.R.), and ' 'the PPP Allowance (grant number LSHM20056, P.D.K.) made available by ' 'Health~Holland, Top Sector Life Sciences & Health, to stimulate public-private ' 'partnerships. The remaining authors declare no competing interests.', 'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}], 'article-number': '3189'}